2022 World Conference on Lung Cancer (Posters)-P1.16-04. Phase 3 EVOKE-01 Study of Sacituzumab Govitecan vs Docetaxel in NSCLC After Prior Platinum and Checkpoint Inhibitors

P1.16-04. Phase 3 EVOKE-01 Study of Sacituzumab Govitecan vs Docetaxel in NSCLC After Prior Platinum and Checkpoint Inhibitors

Back to course

Pdf Summary

The IASLC 2022 World Conference on Lung Cancer Annual Meeting featured a presentation on the EVOKE-01 phase 3 study comparing sacituzumab govitecan to docetaxel in patients with non-small cell lung cancer (NSCLC) that progressed after platinum-based chemotherapy and checkpoint inhibitors. Current standard treatments for metastatic NSCLC include immune checkpoint inhibitors, chemotherapy, or a combination of both, but many patients do not respond or experience disease progression. Sacituzumab govitecan is an antibody-drug conjugate that has been approved for other cancers, and a phase 1/2 study showed promising results in metastatic NSCLC. <br /><br />The EVOKE-01 study is an open-label, global, multicenter, randomized phase 3 trial comparing the efficacy of sacituzumab govitecan to docetaxel in patients with stage IV NSCLC who have progressed after platinum-based chemotherapy and checkpoint inhibitors. The primary endpoint is overall survival, and secondary endpoints include progression-free survival, objective response rate, and safety. Patients must have received prior treatment for actionable genomic alterations, and testing for EGFR, ALK, and PD-L1 is required.<br /><br />Sacituzumab govitecan is a novel antibody-drug conjugate that targets the Trop-2 antigen, which is expressed in many solid cancers, including NSCLC. It consists of an antibody directed towards Trop-2, a linker for the release of SN-38, a potent cytotoxic agent, and a high drug-to-antibody ratio. The drug is designed to release SN-38 in targeted tumor cells, leading to cell death and a bystander effect on adjacent tumor cells.<br /><br />The EVOKE-01 trial began enrollment in 2021 and is currently ongoing at multiple sites worldwide. The study aims to provide evidence on the efficacy and safety of sacituzumab govitecan as a treatment option for patients with metastatic NSCLC who have progressed after standard therapies. The results of this trial will contribute to improving the treatment options for patients with this challenging disease.

Asset Subtitle

Niels Reinmuth, Germany

Meta Tag

Speaker Niels Reinmuth, Germany

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

IASLC 2022 World Conference on Lung Cancer

EVOKE-01 phase 3 study

sacituzumab govitecan

docetaxel

non-small cell lung cancer (NSCLC)

platinum-based chemotherapy

checkpoint inhibitors

metastatic NSCLC

immune checkpoint inhibitors

antibody-drug conjugate